Cite
HARVARD Citation
Dempsey, M. et al. (2018). Long-term cost-effectiveness analysis shows that IDegLira is associated with improved outcomes and lower costs compared with insulin glargine U100 plus insulin aspart in the US. Journal of medical economics. pp. 1110-1118. [Online].